<DOC>
	<DOCNO>NCT00057850</DOCNO>
	<brief_summary>Phase I/II trial study effectiveness combine BMS-247550 cisplatin treat patient metastatic recurrent head neck cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell .</brief_summary>
	<brief_title>BMS-247550 Plus Cisplatin Treating Patients With Metastatic Recurrent Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine recommend phase II dose BMS-247550 administer cisplatin patient metastatic recurrent squamous cell carcinoma head neck . ( Phase I ) II . Determine toxic effect regimen patient . III . Determine response rate , time progression , survival patient treat regimen . ( Phase II ) IV . Determine pharmacokinetics regimen patient . V. Correlate select marker peripheral blood mononuclear cell tumor sample toxicity response patient treat regimen . OUTLINE : This open-label , dose-escalation study BMS-247550 . Phase I : Patients receive BMS-247550 IV 3 hour cisplatin IV 30-60 minute day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos BMS-247550 maximum tolerate dose ( MTD ) determine . The MTD define dose least 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , 10 additional patient receive treatment recommend phase II dose BMS-247550 . Phase II : Patients receive treatment Phase I recommend phase II dose BMS-247550 .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma head neck consider incurable surgery radiotherapy No nasopharyngeal disease primary site Extensive , localregional distant metastatic disease Newly diagnose OR Recurrent disease initial treatment surgery radiotherapy ( include neoadjuvant chemotherapy concurrent chemoradiotherapy ) Measurable disease If site measurable disease previously irradiate area , disease progression radiotherapy must document PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Hematopoietic Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 2.0 mg/dL Transaminases great 2 time upper limit normal ( ULN ) ( 5 time ULN liver involvement ) Renal Creatinine great 1.5 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No evidence active infection No malignancy within past 2 year except curatively treat stage 0 I cancer PRIOR CONCURRENT THERAPY : Chemotherapy No prior chemotherapy recurrent disease Radiotherapy At least 6 month since prior radiotherapy recover Surgery Recovered prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
</DOC>